“We started with Amato from the beginning of our public life, We were an OTC-listed company and Amato developed our full IR strategy, including orchestrating our capital raises and up-list strategy to NASDAQ. Amato is the best in class in the business.” (Robert deRose – Chairman and CEO, Education Lending Group (NASDAQ-listed)/Vice Chairman, Education Finance Division, CIT Corp.)

“Amato has been around for many years and always does a great job for companies.” (Head of Healthcare Investment Bank at NYC-based bulge bracket firm)

“The Amato team were the architects of our company’s successful transition from a private company to a NASDAQ-listed company. We consider Amato’s representative a valuable member of our executive team.” (Patricia Scheller, former CEO and Director of Viveve/former CEO, Prescient Medical, Inc./Executive Director, Ortho Clinical Diagnostics/VP and GM,Dade Behring)

"Amato is the only IR firm I recommend.  The team is very good at closing the value gap that often exists between founders and the investor community.  I've known Gerry Amato for a long time, and I trust him and his opinion.  Gerry’s style is old-school, and his word is his bond – which is very unique on Wall Street." (Barry Michaels, Board Member, Audit Committee Chair, Zynex/ Former CFO, Organovo Holdings/President, Cordis Webster, a Johnson & Johnson Company/VP and Corporate Controller, Medtronic/Group VP, Baxter International)

"Amato is fundamentally different from others in the field due to its level of professionalism, integrity, ability to listen to client’s needs and tailor sophisticated programs to achieve client objectives with the right terms. Amato’s network and the quality of its network is incredible. We were proud to walk around NYC with Gerry and his team." (Sharon Presnell, CEO of a private biotech company/Board of Directors of College Foundation/Board member of an organization affiliated with University of Virginia)

“I’ve been a venture capitalist and CEO of three companies and had never heard of or considered the strategies you and your team discussed. I came away from our call very impressed and look forward to exploring ways to work together.” (CEO of a private biotech company/previously well-known Boston based VC /30 years in the biotechnology industry/ Ph.D. in Genetics from Harvard University/published extensively in scientific journals)